5414002025-10-012025-12-315414002025-04-012025-12-315414002025-10-012025-12-31in-capmkt:OtherExpenses1Member5414002025-04-012025-12-31in-capmkt:OtherExpenses1Member5414002025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15414002025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15414002025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15414002025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRxbrli:pureiso4217:INRxbrli:shares541400ZIMLABNOTLISTEDINE518E01015ZIM Laboratories LimitedMain BoardEquity2025-04-012026-03-312026-02-112026-02-05INRLakhsQuarterlyThird quarterSingle segmentPharmaceutical2026-02-1116:00:002026-02-1118:45:00Not applicable2025-10-012025-12-31UnauditedConsolidated108659300017015000110360800043227600058680004782100015579700034291000503130003167740001043140000604680000604680001497900015130001649200004397600000004397600086670005264300043977000-100052644000-1000487358000100.90.9000.90.90.00440.01420.0276Notes: <BR> <BR> 1 The above unaudited consolidated financial results of ZIM Laboratories Limited the Parent or the Company and its subsidiaries together referred to as Group were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11 February 2026. The above results have been subjected to limited review by Statutory Auditor of the Parent. <BR> 2 These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard Ind AS notified under the Companies Indian Accounting Standards Rules, 2015 as amended as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India SEBI. <BR> 3 The consolidated financial results of the Group for the quarter & nine months ended 31 December 2024 and year ended 31 March 2025 were reviewed audited by another auditor who expressed an unmodified conclusion/opinion on those results on 10 February 2025 and 20 May 2025 respectively. <BR> 4 The Group is principally engaged in a single business segment which is pharmaceuticals. There is no separate reportable segment as per Ind AS 108 Operating Segments. <BR> Place: Nagpur Anwar Daud <BR> Date: 11 February 2026 Managing Director2025-04-012025-12-31UnauditedConsolidated2691267000522080002743475000114343900051087000-120310004651230009892000014875100081547600027107650003271000003271000016061000-433200011729000020981000000020981000161040003708500020982000-100037086000-1000487358000100.430.43000.430.430.00440.01050.0133Other Expenses316774000Other Expenses815476000Measurements of defined employee benefit plans-1899000-1899000Measurements of defined employee benefit plans-5697000-5697000-553000-1659000Exchange differences on translation of foreign operations1001300010013000Exchange differences on translation of foreign operations201420002014200000866700016104000